Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6–17 Years Old): Results From a Pooled Analysis of 2 Studies
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: With increasing use of atypical antipsychotics among pediatric patients, detailed information about safety and tolerability is crucial. METHOD: Data were pooled from two 8-week, randomized, double-blind, multicenter, parallel-group trials comparing aripiprazole versus placebo in subjects aged 6 to 17 years with irritability associated with DSM-IV-TR-diagnosed autistic disorder: one flexibly dosed (aripiprazole 2-15 mg/d; target of 5, 10, or 15 mg/d), the other fixed-dose (aripiprazole 5, 10, or 15 mg/d). The first was conducted from June 2006-April 2008, and the second, from June 2006-June 2008. Adverse events were characterized with respect to incidence, duration, severity, timing of peak incidence of onset, and dose-response relationship. Extrapyramidal symptoms, drooling, and metabolic parameters were evaluated. RESULTS: Three hundred thirteen subjects comprised the safety sample (aripiprazole 212, placebo 101). Discontinuations due to adverse events with aripiprazole versus placebo were, overall, 10.4% versus 6.9%; subjects 6-12 years: 10.8% versus 5.1%; and subjects 13-17 years: 8.9% versus 13.6%. Common adverse events with aripiprazole versus placebo included sedation (20.8% vs 4.0%), fatigue (16.5% vs 2.0%), vomiting (13.7% vs 6.9%), increased appetite (12.7% vs 6.9%), somnolence (10.4% vs 4.0%), and tremor (9.9% vs 0.0%). Most adverse events were mild or moderate and occurred early. Only fatigue showed a dose-response relationship (P < .05). Mean body weight change (last observation carried forward, 1.6 vs 0.4 kg) was higher with aripiprazole than placebo (P < .001). There were no between-treatment differences in metabolic changes. The extrapyramidal symptom-related adverse event incidence with aripiprazole versus placebo was, overall, 20.8% vs 9.9%; the incidence of akathisia-related events was 3.3% vs 8.9%. CONCLUSIONS: Aripiprazole was generally safe and well tolerated in subjects (6-17 years) with irritability associated with autistic disorder in these 8-week studies; clinicians should be aware of this clinical profile and strategies to manage adverse events if they occur. TRIAL REGISTRATION: clinicaltrials.gov Identifiers NCT00332241 and NCT00337571.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613
Self-citationThe Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?
Swartz, H. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0508e15 · Cited by 107
Cited by
An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0100-y · Cited by 987
A randomised controlled trial of bumetanide in the treatment of autism in children
Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., Hadjikhani, N., & Ben-Ari, Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.124 · Cited by 322
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014) · Child Psychiatry & Human Development · doi:10.1007/s10578-013-0390-x · Cited by 134
Murphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
Curran, M. P. (2011) · CNS Drugs · doi:10.2165/11208280-000000000-00000 · Cited by 10
“001).([2,7]) Clinically significant weight gain (‡7% relative to baseline) was reported in 26% of aripiprazole recipients and 7% of placebo recipients.”
BackgroundMethodInfluential
Metadata
- Authors
- Robb, A. S., Andersson, C., Bellocchio, E. E., Manos, G., Rojas-Fernandez, C., Mathew, S., Marcus, R., Owen, R., & Mankoski, R.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-01-06
- Volume
- 13
- Issue
- 1
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- OpenAlex
- W1997443895
- Cited by
- 35
- References
- 3
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6–17 Years Old): Results From a Pooled Analysis of 2 Studies. https://app.cochat.ai/papers/10.4088/pcc.10m01008gry
- The paper
- Robb, A. S., Andersson, C., Bellocchio, E. E., Manos, G., Rojas-Fernandez, C., Mathew, S., Marcus, R., Owen, R., & Mankoski, R. (2011). Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6–17 Years Old): Results From a Pooled Analysis of 2 Studies. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.10m01008gry
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.